From: Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination
 | Children | Adults | All patients | ||||||
---|---|---|---|---|---|---|---|---|---|
N (% total) | Female F:M (ratio) | Age Median (IQR) a | N (% total) | Female F:M (ratio) | Age Median (IQR) a | N (% total) | Female F:M (ratio) | Age Median (IQR) a | |
All phenotypes (All)b | 139 (All) | 73:63 (1.2) | 8 (5–12) | 148 (All) | 92:56 (1.6) | 40 (30–54) | 287 (All) | 165:119 (1.4) | 22 (8–43) |
 Monophasic course | 79 (57) | 39:40 (1) | 7 (4–11) | 57 (39) | 37:20 (1.9) | 43 (30–56) | 136 (47) | 76:60 (1.3) | 14 (6–38) |
 Relapsing course | 44 (32) | 29:15 (1.9) | 8 (6–13) | 61 (41) | 37:24 (1.5) | 40 (33–51) | 105 (37) | 66:39 (1.7) | 30 (10–44) |
 Unknown | 16 (12) | 5:8 (0.6) | 9 (4–13) | 30 (20) | 18:12 (1.5) | 39 (27–53) | 46 (16) | 23:20 (1.2) | 25 (12–49) |
ON | 38 (27 of All) | 26:12 (2.2) | 10 (7–13) | 91 (61 of All) | 58:33 (1.8) | 44 (33–55) | 129 (45 of All) | 84:45 (1.9) | 34 (15–49) |
 Monophasic ON | 22 (58) | 14:8 (1.8) | 9 (7–13) | 43 (47) | 29:14 (2.1) | 46 (33–57) | 65 (50) | 43:22 (2.0) | 32 (12–54) |
 Relapsing ON | 16 (43) | 12:4 (3.0) | 11 (8–16) | 48 (53) | 29:19 (1.5) | 40 (33–51) | 64 (50) | 41:23 (1.8) | 34 (17–49) |
  BON | 18 (47 of ON) | 11:7 (1.6) | 9 (6–14) | 40 (44 of ON) | 25:15 (1.7) | 39 (33–55) | 58 (45 of ON) | 36:22 (1.6) | 33 (13–49) |
   Monophasic BON | 14 (78) | 8:6 (1.3) | 9 (5–13) | 23 (58) | 15:8 (1.9) | 47 (31–57) | 37 (64) | 23:14 (1.6) | 29 (10–49) |
   Relapsing BON | 4 (22) | 3:1 (3.0) | 12 (6–17) | 17 (43) | 10:7 (1.4) | 36 (33–51) | 21(36) | 13:8 (1.6) | 34 (21–49) |
  UON | 17 (45 of ON) | 13:4 (3.3) | 10 (9–13) | 45 (49 of ON) | 29:16 (1.8) | 44 (32–54) | 62 (48 of ON) | 42:20 (2.1) | 34 (17–50) |
   Monophasic UON | 8 (47) | 6:2 (3.0) | 10 (8–13) | 20 (44) | 14:6 (2.3) | 45 (32–59) | 28 (45) | 20:8 (2.5) | 34 (14–54) |
   Relapsing UON | 9 (53) | 7:2 (3.5) | 11 (8–15) | 25 (56) | 15:10 (1.5) | 40 (32–53) | 34 (55) | 22:12 (1.8) | 34 (17–50) |
  Relapsing ON mixed | 3 (8 of ON) | 2:1 (2.0) | 10 (9–15) | 6 (7 of ON) | 4:2 (2.0) | 49 (36–58) | 9 (7 of ON) | 6:3 (2.0) | 39 (12–52) |
ADEM | 53 (38 of All) | 5 (3–8) | 5 (3–8) | 1 (1 of All) | 1:0 (−) | 25 (−) | 54 (19 of All) | 28:26 (1.1) | 5 (3–8) |
 Monophasic ADEM | 42 (79) | 20:22 (0.9) | 4 (3–8) | – | – | – | 42 (78) | 20:22 (0.9) | 4 (3–8) |
 Relapsing ADEMc | 11 (21) | 7:4 (1.8) | 6 (5–8) | 1 (100) | 1:0 (−) | 25 (−) | 12 (22) | 8:4 (2.0) | 6 (5–9) |
ON/TM | – | – | – | 9 (6 of All) | 5:4 (1.3) | 54 (28–59) | 9 (3 of All) | 5:4 (1.3) | 54 (28–59) |
 Monophasic ON/TM | – | – | – | 3 (33) | 2:1 (2.0) | 54 (43–60) | 3 (33) | 2:1 (2.0) | 54 (43–60) |
 Relapsing ON/TM | – | – | – | 6 (67) | 3:3 (1.0) | 44 (25–58) | 6 (67) | 3:3 (1.0) | 44 (25–58) |
LETM | 10 (7 of All) | 3:7 (0.4) | 11 (6–15) | 8 (5 of All) | 5:3 (1.7) | 28 (24–33) | 18 (6 of All) | 8:10 (0.8) | 18 (10–29) |
 Monophasic LETM | 10 (100) | 3:7 (0.4) | 11 (6–15) | 7 (88) | 4:3 (1.3) | 26 (23–31) | 17 (94) | 7:10 (0.9) | 17 (9–26) |
 Relapsing LETM | – | – | – | 1 (13) | 1:0 (−) | 34 (−) | 1 (6) | 1:0 (−) | 34 (−) |
Relapsing ADEM/ON | 10 (7 of All) | 4:5 (0.8) | 6 (5–10) | – | – | – | 10 (3 of All) | 4:5 (0.8) | 6 (5–10) |
Monophasic CIS | 1 (1 of All) | 1:0 (−) | 5 (−) | – | – | – | 1 (1 of All) | 1:0 (−) | 5 (−) |
Otherd | 5 (3 of All) | 2:3 (0.7) | 10 (6–15) | 7 (5 of All) | 3:4 (0.8) | 32 (27–42) | 12 (4 of All) | 5:7 (0.6) | 28 (15–40) |
Phenotypes n < 3e | 6 (4 of All) | 5:2 (2.5) | 8 (6–11) | 9 (6 of All) | 5:4 (1.3) | 40 (33–44) | 15 (5 of All) | 10:6 (1.7) | 25 (8–42) |
Unknown Phenotype | 16 (11 of All) | 5:8 (0.6) | 9 (4–13) | 23 (16 of All) | 15:8 (1.9) | 43 (26–54) | 39 (14 of All) | 20:16 (1.3) | 25 (12–49) |